These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

87 related items for PubMed ID: 10215649

  • 1. SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. II. In vivo pharmacological characterization.
    Bignon E, Alonso R, Arnone M, Boigegrain R, Brodin R, Gueudet C, Héaulme M, Keane P, Landi M, Molimard JC, Olliero D, Poncelet M, Seban E, Simiand J, Soubrié P, Pascal M, Maffrand JP, Le Fur G.
    J Pharmacol Exp Ther; 1999 May; 289(2):752-61. PubMed ID: 10215649
    [Abstract] [Full Text] [Related]

  • 2. SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies.
    Bignon E, Bachy A, Boigegrain R, Brodin R, Cottineau M, Gully D, Herbert JM, Keane P, Labie C, Molimard JC, Olliero D, Oury-Donat F, Petereau C, Prabonnaud V, Rockstroh MP, Schaeffer P, Servant O, Thurneyssen O, Soubrié P, Pascal M, Maffrand JP, Le Fur G.
    J Pharmacol Exp Ther; 1999 May; 289(2):742-51. PubMed ID: 10215648
    [Abstract] [Full Text] [Related]

  • 3. SR146131, a cholecystokinin-A receptor agonist, antagonizes prepulse inhibition deficits produced by dizocilpine and DOI.
    Shilling PD, Feifel D.
    Psychopharmacology (Berl); 2002 Nov; 164(3):285-93. PubMed ID: 12424552
    [Abstract] [Full Text] [Related]

  • 4. Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist.
    Antal-Zimanyi I, Bruce MA, Leboulluec KL, Iben LG, Mattson GK, McGovern RT, Hogan JB, Leahy CL, Flowers SC, Stanley JA, Ortiz AA, Poindexter GS.
    Eur J Pharmacol; 2008 Aug 20; 590(1-3):224-32. PubMed ID: 18573246
    [Abstract] [Full Text] [Related]

  • 5. In vivo pharmacology of L-364,718, a new potent nonpeptide peripheral cholecystokinin antagonist.
    Lotti VJ, Pendleton RG, Gould RJ, Hanson HM, Chang RS, Clineschmidt BV.
    J Pharmacol Exp Ther; 1987 Apr 20; 241(1):103-9. PubMed ID: 2437282
    [Abstract] [Full Text] [Related]

  • 6. Pharmacological profile of a new serine derivative cholecystokinin receptor antagonist TP-680 on pancreatic, biliary and gastric function.
    Tachibana I, Kanagawa K, Yamamoto Y, Otsuki M.
    J Pharmacol Exp Ther; 1996 Dec 20; 279(3):1404-12. PubMed ID: 8968365
    [Abstract] [Full Text] [Related]

  • 7. Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): in vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity.
    Dawson LA, Hughes ZA, Starr KR, Storey JD, Bettelini L, Bacchi F, Arban R, Poffe A, Melotto S, Hagan JJ, Price GW.
    Neuropharmacology; 2006 Jun 20; 50(8):975-83. PubMed ID: 16581092
    [Abstract] [Full Text] [Related]

  • 8. 3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a novel, potent, and selective cholecystokinin 1 receptor antagonist: in vitro and in vivo pharmacological comparison with dexloxiglumide.
    Morton MF, Barrett TD, Yan W, Freedman JM, Lagaud G, Prendergast CE, Moreno V, Pyati J, Figueroa K, Li L, Wu X, Rizzolio M, Breitenbucher JG, McClure K, Shankley NP.
    J Pharmacol Exp Ther; 2007 Nov 20; 323(2):562-9. PubMed ID: 17684117
    [Abstract] [Full Text] [Related]

  • 9. L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist.
    Kanatani A, Ishihara A, Iwaasa H, Nakamura K, Okamoto O, Hidaka M, Ito J, Fukuroda T, MacNeil DJ, Van der Ploeg LH, Ishii Y, Okabe T, Fukami T, Ihara M.
    Biochem Biophys Res Commun; 2000 May 27; 272(1):169-73. PubMed ID: 10872822
    [Abstract] [Full Text] [Related]

  • 10. The novel neuropeptide Y Y(1) receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability.
    Kanatani A, Kanno T, Ishihara A, Hata M, Sakuraba A, Tanaka T, Tsuchiya Y, Mase T, Fukuroda T, Fukami T, Ihara M.
    Biochem Biophys Res Commun; 1999 Dec 09; 266(1):88-91. PubMed ID: 10581170
    [Abstract] [Full Text] [Related]

  • 11. Cholecystokinin antagonistic activities of loxiglumide.
    Wakatsuki K, Saito T, Saeki M, Ninomiya K, Kasai H, Kimura K, Fujii M.
    Arzneimittelforschung; 1997 Oct 09; 47(10):1130-3. PubMed ID: 9368707
    [Abstract] [Full Text] [Related]

  • 12. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
    Millan MJ, Svenningsson P, Ashby CR, Hill M, Egeland M, Dekeyne A, Brocco M, Di Cara B, Lejeune F, Thomasson N, Munoz C, Mocaër E, Crossman A, Cistarelli L, Girardon S, Iob L, Veiga S, Gobert A.
    J Pharmacol Exp Ther; 2008 Feb 09; 324(2):600-11. PubMed ID: 18024787
    [Abstract] [Full Text] [Related]

  • 13. Region specific galanin receptor/neuropeptide Y Y1 receptor interactions in the tel- and diencephalon of the rat. Relevance for food consumption.
    Parrado C, Díaz-Cabiale Z, García-Coronel M, Agnati LF, Coveñas R, Fuxe K, Narváez JA.
    Neuropharmacology; 2007 Feb 09; 52(2):684-92. PubMed ID: 17087983
    [Abstract] [Full Text] [Related]

  • 14. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
    Fong TM, Guan XM, Marsh DJ, Shen CP, Stribling DS, Rosko KM, Lao J, Yu H, Feng Y, Xiao JC, Van der Ploeg LH, Goulet MT, Hagmann WK, Lin LS, Lanza TJ, Jewell JP, Liu P, Shah SK, Qi H, Tong X, Wang J, Xu SS, Francis B, Strack AM, MacIntyre DE, Shearman LP.
    J Pharmacol Exp Ther; 2007 Jun 09; 321(3):1013-22. PubMed ID: 17327489
    [Abstract] [Full Text] [Related]

  • 15. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
    Shearman LP, Stribling DS, Camacho RE, Rosko KM, Wang J, Tong S, Feng Y, Marsh DJ, Yu H, Guan X, Spann SK, Macneil DJ, Fong TM, Metzger JM, Goulet MT, Hagmann WK, Plummer CW, Finke PE, Mills SG, Shah SK, Truong Q, Van der Ploeg LH, Macintyre DE, Strack AM.
    Eur J Pharmacol; 2008 Jan 28; 579(1-3):215-24. PubMed ID: 18021763
    [Abstract] [Full Text] [Related]

  • 16. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.
    Iravani MM, Tayarani-Binazir K, Chu WB, Jackson MJ, Jenner P.
    J Pharmacol Exp Ther; 2006 Dec 28; 319(3):1225-34. PubMed ID: 16959959
    [Abstract] [Full Text] [Related]

  • 17. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
    Millan MJ, Di Cara B, Hill M, Jackson M, Joyce JN, Brotchie J, McGuire S, Crossman A, Smith L, Jenner P, Gobert A, Peglion JL, Brocco M.
    J Pharmacol Exp Ther; 2004 Jun 28; 309(3):921-35. PubMed ID: 14978195
    [Abstract] [Full Text] [Related]

  • 18. Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor.
    Cirillo R, Gillio Tos E, Schwarz MK, Quattropani A, Scheer A, Missotten M, Dorbais J, Nichols A, Borrelli F, Giachetti C, Golzio L, Marinelli P, Thomas RJ, Chevillard C, Laurent F, Portet K, Barberis C, Chollet A.
    J Pharmacol Exp Ther; 2003 Jul 28; 306(1):253-61. PubMed ID: 12660315
    [Abstract] [Full Text] [Related]

  • 19. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P.
    Mov Disord; 2004 Jan 28; 19(1):15-21. PubMed ID: 14743355
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC).
    Suzuki G, Kimura T, Satow A, Kaneko N, Fukuda J, Hikichi H, Sakai N, Maehara S, Kawagoe-Takaki H, Hata M, Azuma T, Ito S, Kawamoto H, Ohta H.
    J Pharmacol Exp Ther; 2007 Jun 28; 321(3):1144-53. PubMed ID: 17360958
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.